ライフサイエンスコーパス: peginterferon

1 ) were less common with sofosbuvir than with peginterferon.

2 were less frequent with sofosbuvir than with peginterferon.

3 was suspected to be a direct complication of peginterferon.

4 ed and as related or not to complications of peginterferon.

5 atients with an adequate initial response to peginterferon.

6 score and baseline HCV RNA level, to receive peginterferon 1.5 mug/kg per week with weight-based riba

7 ebo (2:2:1) for 12 weeks in combination with peginterferon (180 mug per week) and ribavirin (1000-120

8 domized to 12 weeks of TVR (750 mg q8h) plus peginterferon (180 mug/week) and ribavirin (1,000-1,200

9 aprevir (750 mg every 8 h), placebo plus PR (peginterferon, 180 mug, once weekly and ribavirin, 400 m

10 nite, 20 presumed): 37 of 515 who were given peginterferon (7.2%) and 51 of 533 controls (9.6%; P = .

11 hronic hepatitis B respond to treatment with peginterferon alfa (PEG-IFN).

12 eive simeprevir (150 mg once daily, orally), peginterferon alfa 2a (180 mug once weekly, subcutaneous

13 Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in

14 3/4A protease inhibitor versus placebo, plus peginterferon alfa 2a or 2b plus ribavirin was assessed

15 lacebo group) for 12 weeks, followed by just peginterferon alfa 2a or 2b plus ribavirin.

16 evir group) or placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin (placebo gro

17 Addition of simeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus riba

18 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (placebo group).

19 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (simeprevir group),

20 simeprevir (150 mg once daily, orally) plus peginterferon alfa 2a plus ribavirin for 12 weeks, follo

21 n (simeprevir group), or placebo orally plus peginterferon alfa 2a plus ribavirin for 12 weeks, follo

22 ly, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in tr

23 g the adverse event profiles associated with peginterferon alfa 2a plus ribavirin.

24 a 2a, and ribavirin was superior to placebo, peginterferon alfa 2a, and ribavirin (SVR12 in 210 [80%]

25 Treatment with simeprevir, peginterferon alfa 2a, and ribavirin was superior to pla

26 00 mg/day) (n = 58 in the final analysis) or peginterferon alfa 2b (1.5 mcg/kg/wk), ribavirin (1000-1

27 imeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus ribavirin improved SVR in tre

28 ot have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood o

29 ups, and were typical of those expected from peginterferon alfa and ribavirin therapy.

30 In HCV-infected patients in whom initial peginterferon alfa and ribavirin treatment failed, retre

31 rant of, or ineligible for and intolerant of peginterferon alfa plus ribavirin.

32 ing the known adverse events associated with peginterferon alfa plus ribavirin.

33 treatment-naive; previous non-responders to peginterferon alfa plus ribavirin; or medically ineligib

34 249 [97%] vs 132 [99%]), irrespective of the peginterferon alfa used.

35 then 750 mg every 8 hours) for 12 weeks and peginterferon alfa-2a (180 microg per week) and ribaviri

36 otent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these pa

37 in which patients received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by

38 daily) alone (Group A, 11 patients) or with peginterferon alfa-2a and ribavirin (Group B, 10 patient

39 group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patient

40 were randomized 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in comb

41 ty of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs

42 or 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks i

43 bavirin for 12 weeks followed by 36 weeks of peginterferon alfa-2a and ribavirin alone.

44 rin was more effective than retreatment with peginterferon alfa-2a and ribavirin alone.

45 previous null responders with simeprevir and peginterferon alfa-2a and ribavirin and telaprevir and p

46 of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy

47 : a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR

48 vir placebo (once a day) in combination with peginterferon alfa-2a and ribavirin for 12 weeks followe

49 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patien

50 Nonresponders with HCV genotype 1 were given peginterferon alfa-2a and ribavirin for 2 weeks (course

51 group, receiving telaprevir for 24 weeks and peginterferon alfa-2a and ribavirin for 48 weeks (at the

52 ts to the PR48 (or control) group, receiving peginterferon alfa-2a and ribavirin for 48 weeks (at the

53 , all 10 (100%) who received sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks had a su

54 monotherapy for 12 weeks or sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks.

55 ribavirin was non-inferior to telaprevir and peginterferon alfa-2a and ribavirin for SVR12 (54% [203/

56 istered a 12-week regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with

57 Peginterferon alfa-2a and ribavirin therapy provides goo

58 ron alfa-2a and ribavirin and telaprevir and peginterferon alfa-2a and ribavirin treatment, respectiv

59 nders during at least one previous course of peginterferon alfa-2a and ribavirin treatment.

60 reatment with telaprevir in combination with peginterferon alfa-2a and ribavirin was more effective t

61 Simeprevir and peginterferon alfa-2a and ribavirin was non-inferior to

62 Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated i

63 , and 900 mg every 12 hours) or placebo plus peginterferon alfa-2a and ribavirin, followed by peginte

64 atment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated

65 nterferon alfa-2a and ribavirin, followed by peginterferon alfa-2a and ribavirin.

66 who were given placebo received 48 weeks of peginterferon alfa-2a and ribavirin.

67 d SVR48 after treatment intensification with peginterferon alfa-2a and ribavirin.

68 t-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.

69 , or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin.

70 cacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin.

71 ht >/=85 kg), a 12-week induction regimen of peginterferon alfa-2a and/or higher-dose ribavirin is no

72 elaprevir at a dose of 750 mg every 8 hours, peginterferon alfa-2a at a dose of 180 mug per week, and

73 Peginterferon alfa-2a could be an effective therapy for

74 Additional groups included 360 mug/wk peginterferon alfa-2a for 12 weeks then 180 mug/wk pegin

75 o the T24P24 group, receiving telaprevir and peginterferon alfa-2a for 24 weeks (at the same doses as

76 erferon alfa-2a for 12 weeks then 180 mug/wk peginterferon alfa-2a for 36 weeks plus 1200 mg/day riba

77 Three of these groups also received peginterferon alfa-2a for 4, 8, or 12 weeks.

78 Patients were randomized to 180 mug/wk peginterferon alfa-2a for 48 weeks plus 1200 mg/day riba

79 ve sofosbuvir plus ribavirin for 12 weeks or peginterferon alfa-2a plus ribavirin for 24 weeks.

80 , underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin.

81 We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin.

82 erences among the 4 groups or between pooled peginterferon alfa-2a regimens (A + B vs C + D: odds rat

83 The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates

84 The strength of peginterferon alfa-2a-induced IFIG response significantl

85 subset, a potential prognostic indicator in peginterferon alfa-2a-treated patients with HIV infectio

86 -associated Kaposi sarcoma were treated with peginterferon alfa-2a.

87 ed volunteers were treated for 12 weeks with peginterferon alfa-2a.

88 tional study enrolling patients treated with peginterferon alfa-2a/ribavirin (PEG/RBV) with or withou

89 revir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with ge

90 405 patients treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, vi

91 (PR48), combined with a total of 48 weeks of peginterferon alfa-2a/ribavirin.

92 Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) signi

93 infection were randomly assigned to receive peginterferon alfa-2b 1.5 mug/kg plus ribavirin 800-1400

94 00-1400 mg daily for 48 weeks (PR48; n=104); peginterferon alfa-2b and ribavirin daily for 4 weeks, f

95 In all three groups, peginterferon alfa-2b and ribavirin were administered fo

96 virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin.

97 and ribavirin daily for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg

98 4; n=103) or 44 weeks (PR4/PRB44; n=103); or peginterferon alfa-2b, ribavirin, and boceprevir three t

99 not had a sustained virologic response after peginterferon alfa-ribavirin therapy to one of four trea

100 c failure with telaprevir or boceprevir plus peginterferon alfa-ribavirin).

101 Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens wer

102 evir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustaine

103 a from ribavirin (RBV)-related hemolysis and peginterferon-alfa (PEG-IFN)-related bone marrow suppres

104 combination of boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of pa

105 Combined with peginterferon-alfa plus ribavirin they offer genotype-1

106 virin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197)

107 f sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients wi

108 Peginterferon alpha and RBV can significantly affect lip

109 Retreatment with peginterferon alpha and ribavirin (PR) offers a limited

110 ls (RCTs) show that triple therapy (TT) with peginterferon alpha, ribavirin, and boceprevir (BOC) or

111 corded coffee intake before retreatment with peginterferon alpha-2a (180 mug/wk) and ribavirin (1000-

112 prove virologic response rates compared with peginterferon alpha-2a plus ribavirin alone.

113 resistance to receive either standard care (peginterferon alpha-2a plus ribavirin for 48 weeks, n =

114 ioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several i

115 randomly assigned to groups that were given peginterferon alpha-2a, with or without ribavirin, for 4

116 pha-2b-ribavirin, and 47% in genotype 1 with peginterferon alpha-2a-ribavirin.

117 nt, the decrease from baseline to Week 12 of peginterferon alpha-2a/ribavirin treatment in mean log(1

118 d 1:1 to 20 weeks of additional therapy with peginterferon alpha-2b and ribavirin (double therapy) or

119 68 HCV patients receiving antiviral therapy (peginterferon alpha-2b and ribavirin) we performed a lon

120 After 4 weeks of lead-in therapy with peginterferon alpha-2b and ribavirin, 101 patients (48%)

121 ribavirin (double therapy) or to 24 weeks of peginterferon alpha-2b, ribavirin, and boceprevir (tripl

122 fection, estimated at 53% in genotype 1 with peginterferon alpha-2b-ribavirin, and 47% in genotype 1

123 The effect of peginterferon alpha/ribavirin (PEG-IFN/RBV) and hepatiti

124 n associated with poor virologic response to peginterferon alpha/ribavirin (PR) in chronic hepatitis

125 th polyethylene glycol decorated interferon (peginterferon) alpha and ribavirin (PR) is associated wi

126 HCV antiviral treatment (peginterferon-alpha + ribavirin) has been shown to be co

127 onic hepatitis C (CHC) who were treated with peginterferon-alpha and ribavirin.

128 ron were prospectively randomized to receive peginterferon-alpha-2a (180 mug/d) plus either RBV stand

129 any one of the new DAAs is given along with peginterferon-alpha/ribavirin, clinical trials exploring

130 Telaprevir (TVR) plus peginterferon-alpha2a (PEG-IFN-alpha2a) and ribavirin su

131 and safety of the combination of simeprevir, peginterferon-alpha2a (PegIFN), and ribavirin (RBV) in p

132 virus (HCV) genotype 2/3 infection receiving peginterferon-alpha2a and lower, conventional 800 mg dai

133 Prolonged, low-dose peginterferon-alpha2a therapy and beta-blockers did not

134 Prolonged low-dose peginterferon-alpha2a therapy and beta-blockers do not r

135 The peginterferon and entecavir monotherapy groups also diff

136 When utilized with peginterferon and RBV for 12 weeks in treatment-naive pa

137 sis who did not respond to a prior course of peginterferon and ribavirin (44.3% relapsers or patients

138 fully treated with a protease inhibitor with peginterferon and ribavirin (50% could have compensated

139 ts (61%) had not responded to treatment with peginterferon and ribavirin (null responders), and 32 (3

140 he efficacy and tolerability of MK-5172 with peginterferon and ribavirin (PR) in treatment-naive pati

141 d the efficacy and safety of sofosbuvir plus peginterferon and ribavirin (SOF+Peg-IFN+RBV) administer

142 ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 2

143 d -experienced patients, in conjunction with peginterferon and ribavirin (triple therapy), in phase 3

144 agent boceprevir to standard treatment with peginterferon and ribavirin after a 4-week lead-in seems

145 who also had better on-treatment response to peginterferon and ribavirin during follow up.

146 s (cohort B), or 12 weeks of sofosbuvir plus peginterferon and ribavirin followed by 12 weeks of eith

147 Patients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks o

148 Patients received sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks (cohort A) or f

149 se 2 and 3 trials, of sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks in treatment-na

150 ) received open-label sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks.

151 D-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir,

152 0-1200 mg daily), after which they continued peginterferon and ribavirin for an additional 12 weeks o

153 Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C viru

154 Finally, the continued role of peginterferon and ribavirin in future therapies will be

155 the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced pat

156 with HCV genotype 1 infections, therapy with peginterferon and ribavirin is associated with decreases

157 who have not had a response to therapy with peginterferon and ribavirin may benefit from the additio

158 a rapid virologic response after 4 weeks of peginterferon and ribavirin therapy are likely to achiev

159 atients with advanced hepatitis C who failed peginterferon and ribavirin therapy, the rate of liver-r

160 among patients who had not cleared virus on peginterferon and ribavirin therapy.

161 naemia and neutropenia--were associated with peginterferon and ribavirin treatment.

162 roximately one-half the rate of whites after peginterferon and ribavirin treatment.

163 ype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16

164 is review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis o

165 The combination of peginterferon and ribavirin with telaprevir or boceprevi

166 and cirrhosis respond to the combination of peginterferon and ribavirin with telaprevir or boceprevi

167 ost patients had failed prior treatment with peginterferon and ribavirin without (46%) or with telapr

168 HCV RNA after >/=12 weeks of treatment with peginterferon and ribavirin).

169 onse of patients with chronic hepatitis C to peginterferon and ribavirin, little is known regarding i

170 or partial response to previous therapy with peginterferon and ribavirin, received daily doses of 150

171 ined virologic response after treatment with peginterferon and ribavirin, with or without a protease

172 thout cirrhosis who received telaprevir with peginterferon and ribavirin.

173 f boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin.

174 --were consistent with those associated with peginterferon and ribavirin.

175 r had not responded to previous therapy with peginterferon and ribavirin.

176 tients with chronic hepatitis C treated with peginterferon and ribavirin.

177 , without cirrhosis, previously treated with peginterferon and ribavirin.

178 reatment compared with pegylated interferon (peginterferon) and ribavirin alone (56% vs 34% overall;

179 mbination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-cirrhotic treatment-

180 ously not responded to pegylated interferon (peginterferon) and ribavirin or were treatment naive.

181 viral clearance after pegylated interferon (peginterferon) and ribavirin therapy.

182 oceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which increases rates of S

183 y to standard doses of pegylated interferon (peginterferon) and ribavirin.

184 B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, odds ratios for dri

185 f response to the combination of telaprevir, peginterferon, and ribavirin (group 1: 96.6%; 95% confid

186 on and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 we

187 tis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which h

188 th cirrhosis, the combination of sofosbuvir, peginterferon, and ribavirin for 12 weeks produces high

189 ely, and 94% for those receiving sofosbuvir, peginterferon, and ribavirin for 12 weeks.

190 hepatitis C virus (HCV) protease inhibitor, peginterferon, and ribavirin is the standard of care for

191 vely, and 93% in those receiving sofosbuvir, peginterferon, and ribavirin.

192 similar population treated with telaprevir, peginterferon, and ribavirin.

193 SAMe might be a useful adjunct to peginterferon-based therapies in chronic HCV infection.

194 ratified by site, to placebo or subcutaneous peginterferon beta-1a 125 mug once every 2 weeks or ever

195 We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the

196 After 48 weeks, peginterferon beta-1a significantly reduced relapse rate

197 e most common adverse events associated with peginterferon beta-1a were injection site reactions, inf

198 Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment

199 We investigated whether peginterferon decreases the incidence of HCC in the HALT

200 intenance therapy with pegylated interferon (peginterferon) does not reduce liver disease progression

201 re randomly assigned (500 to placebo, 512 to peginterferon every 2 weeks, 500 to peginterferon every

202 ts taking placebo, 481 (94%) patients taking peginterferon every 2 weeks, and 472 (94%) patients taki

203 every 2 weeks, and 472 (94%) patients taking peginterferon every 4 weeks reported adverse events incl

204 , 512 to peginterferon every 2 weeks, 500 to peginterferon every 4 weeks); 1332 (88%) patients comple

205 The peginterferon-experienced patients had a lower HCC incid

206 cohort analysis (P = .009 for comparison of peginterferon-experienced vs nucleotide analogue-treated

207 Long-term maintenance peginterferon in patients with advanced chronic hepatiti

208 ith SOF and ribavirin (RBV), with or without peginterferon, including 54% with cirrhosis and 49% who

209 HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a re

210 cohort (n = 64) of CHB patients treated with peginterferon/nucleotide analogue combination therapy.

211 ven the combination therapy than those given peginterferon only (7.6- vs 3.8-fold; P = .01); however,

212 omly assigned to groups given a half-dose of peginterferon or no treatment (controls) for 3.5 years a

213 o 48 weeks in one of the following arms: (1) peginterferon (PEG-IFN) alfa-2b at 1.5 microg/kg/week wi

214 ely than whites to respond to treatment with peginterferon (PEG-IFN) plus ribavirin (RBV).

215 face antigen (HBsAg) may predict response to peginterferon (PEG-IFN) therapy in chronic hepatitis B (

216 sferase (ALT) flares occur frequently during peginterferon (PEG-IFN) therapy.

217 Peginterferon (PEG-IFN) treatment of hepatitis B e antig

218 s with genotype 1 HCV infection who received peginterferon (PEG-IN) alfa-2a plus ribavirin therapy fo

219 imeprevir was recently approved for use with peginterferon (PEGINF) and ribavirin (RBV) in patients w

220 ined virological response (SVR) rates during peginterferon plus ribavirin (RBV) therapy.

221 Peginterferon plus ribavirin achieves sustained virologi

222 fection, the main genotype worldwide, is now peginterferon plus ribavirin and a protease inhibitor.

223 predictor of improved virologic response to peginterferon plus ribavirin in patients with hepatitis

224 had history of prior treatment failure with peginterferon plus ribavirin therapy.

225 vious null response to pegylated interferon (peginterferon) plus ribavirin (PR-null responders).

226 red with 84% of 19 patients treated with SOF/peginterferon/RBV.

227 For genotype 1, we compare: (1) peginterferon + ribavirin + telaprevir for 12 weeks, fol

228 ith genotype 2, 24 weeks for genotype 3; (3) peginterferon + ribavirin as initial treatment, 24 weeks

229 eks, followed by 12 or 24 weeks treatment of peginterferon + ribavirin dependent on HCV RNA level at

230 fective as second-phase treatments following peginterferon + ribavirin initial treatment for genotype

231 or patients with cirrhosis; (5) sofosbuvir + peginterferon + ribavirin, 12 weeks for patients with or

232 s 2 and 3, treatment strategies include: (1) peginterferon + ribavirin, 24 weeks for treatment-naive

233 HCV) genotype 1 includes triple therapy with peginterferon, ribavirin, and a protease inhibitor.

234 r management of anemia in patients receiving peginterferon, ribavirin, and boceprevir for HCV infecti

235 We compared a regimen of peginterferon, ribavirin, and sofosbuvir with a regimen

236 iral relapse rate, than a 12-week regimen of peginterferon, ribavirin, and sofosbuvir.

237 avirin for 12 weeks, followed by 36 weeks of peginterferon-ribavirin (PR group).

238 irin for 12 weeks (T12PR group), followed by peginterferon-ribavirin alone for 12 weeks if HCV RNA wa

239 th peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved effica

240 th peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, was associated with signi

241 c HCV genotype 1 infection, as compared with peginterferon-ribavirin alone.

242 eiving telaprevir than among those receiving peginterferon-ribavirin alone.

243 Three patients who received boceprevir plus peginterferon-ribavirin and four controls had HIV virolo

244 rrhosis who had previously been treated with peginterferon-ribavirin and had a relapse, a partial res

245 s of sustained virological response (SVR) to peginterferon-ribavirin are low in patients with hepatit

246 Boceprevir in combination with peginterferon-ribavirin could be an important therapeuti

247 ) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatme

248 criteria; or a group receiving placebo with peginterferon-ribavirin for 12 weeks, followed by 36 wee

249 r 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a d

250 received treatment previously, a regimen of peginterferon-ribavirin for 24 weeks, with telaprevir fo

251 group 2, a total of 44% of patients received peginterferon-ribavirin for 28 weeks.

252 r 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 32 weeks, and patients with

253 feron-ribavirin for 8 weeks and placebo with peginterferon-ribavirin for 4 weeks (T8PR group), follow

254 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks.

255 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks.

256 1 (the control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received b

257 roup 1 (control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received b

258 ime point; a group receiving telaprevir with peginterferon-ribavirin for 8 weeks and placebo with peg

259 CV RNA level at week 8 received placebo plus peginterferon-ribavirin for an additional 12 weeks; and

260 between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks; and

261 effect of the combination of boceprevir and peginterferon-ribavirin for retreatment of patients with

262 both the sofosbuvir-ribavirin group and the peginterferon-ribavirin group.

263 enced participants who had been treated with peginterferon-ribavirin had HCV genotype 2 or 3, for a t

264 (T8PR group), followed by 12 or 36 weeks of peginterferon-ribavirin on the basis of the same HCV RNA

265 00-1400 mg per day) for 4 weeks, followed by peginterferon-ribavirin plus either placebo (control gro

266 The addition of boceprevir to peginterferon-ribavirin resulted in significantly higher

267 Peginterferon-ribavirin therapy is the current standard

268 irus (HCV) genotype 1 often need 48 weeks of peginterferon-ribavirin treatment for a sustained virolo

269 pe 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-

270 Telaprevir with peginterferon-ribavirin, as compared with peginterferon-

271 ition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard thera

272 ot have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are

273 ngle-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly gen

274 had received retreatment with telaprevir and peginterferon-ribavirin.

275 per day, for 12 weeks (T12PR12), followed by peginterferon-ribavirin.

276 in patients who were previously treated with peginterferon-ribavirin.

277 mediately (T12/PR48) or following 4 weeks of peginterferon/ribavirin (lead-in T12/PR48), or 12 weeks

278 notype 1 patients with hepatitis C and prior peginterferon/ribavirin (PR) treatment failure.

279 In comparison with peginterferon/ribavirin alone, boceprevir with peginterf

280 (N = 7,163) age >/= 18 years were prescribed peginterferon/ribavirin at the discretion of the treatin

281 Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and

282 ginterferon/ribavirin alone, boceprevir with peginterferon/ribavirin significantly improves sustained

283 s C virus (HCV)-infected patients with prior peginterferon/ribavirin treatment failure (including rel

284 ve a sustained virologic response (SVR) with peginterferon/ribavirin would be useful in optimizing tr

285 vel resistance; virologic failure during the peginterferon/ribavirin-treatment phase was associated w

286 chieve undetectable viremia after 4 weeks of peginterferon/ribavirin.

287 s of the HALT-C cohort showed that long-term peginterferon therapy does not reduce the incidence of H

288 ized controlled study of long-term, low-dose peginterferon therapy in patients with advanced chronic

289 and viral mutagenesis during early stages of peginterferon therapy with and without ribavirin.

290 entecavir-treated and pegylated interferon (peginterferon)-treated patients.

291 tly suppressed to levels lower than those of peginterferon-treated patients (P < .001).

292 tecavir-treated patients with HCC but not in peginterferon-treated patients (P = .015).

293 Because maintenance peginterferon treatment did not alter liver disease prog

294 Patients with cirrhosis who received peginterferon treatment had a lower risk of HCC than con

295 randomized study of 3.5 years of maintenance peginterferon treatment on liver disease progression amo

296 treated patients; P = .022 for comparison of peginterferon- vs entecavir-treated patients).

297 Treatment by peginterferon was associated with a lower HCC incidence

298 one trial, patients for whom treatment with peginterferon was not an option received oral sofosbuvir

299 Among patients for whom treatment with peginterferon was not an option, the rate of a sustained

300 infection who received either sofosbuvir or peginterferon with ribavirin had nearly identical rates